Condition
Acute Rejection
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 3 (1)
Trial Status
Terminated2
Unknown1
Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT01644903Recruiting
Proteogenomic Monitoring and Assessment of Liver Transplant Recipients
NCT05411926Unknown
Effect of PD-1 /PD-L1 Inhibitor Therapy Before Liver Transplantation on Acute Rejection After Liver Transplantation in Patients With Hepatocellular Carcinoma
NCT01117662Phase 3TerminatedPrimary
Efficacy of Rituximab in Acute Cellular Rejection in Renal Transplant Patients
NCT00579592Not ApplicableTerminatedPrimary
Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation
Showing all 4 trials